In Vitro Activity and Microbiological Efficacy of Tedizolid (TR-700) against Gram-Positive Clinical Isolates from a Phase 2 Study of Oral Tedizolid Phosphate (TR-701) in Patients with Complicated Skin and Skin Structure Infections
Authors:
Open Access
- 1 September 2012
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (9) , 4608-4613
Abstract
Tedizolid (TR-700, formerly torezolid) is the active moiety of the prodrug tedizolid phosphate (TR-701), a next-generation oxazolidinone, with high potency against Gram-positive species, including methicillin-resistant Staphylococcus aureus (MRSA). A recently completed randomized, double-blind phase 2 trial evaluated 200, 300, or 400 mg of oral tedizolid phosphate once daily for 5 to 7 days in patients with complicated skin and skin structure infections. This report examines the in vitro activity of tedizolid and Zyvox (linezolid) against Gram-positive pathogens isolated at baseline and describes the microbiological and clinical efficacy of tedizolid. Of 196 isolates tested, 81.6% were S. aureus , and of these, 76% were MRSA. The MIC 50 and MIC 90 of tedizolid against both methicillin-susceptible S. aureus (MSSA) and MRSA were 0.25 μg/ml, compared with a MIC 50 of 1 μg/ml and MIC 90 of 2 μg/ml for linezolid. For coagulase-negative staphylococci ( n = 7), viridans group streptococci ( n = 15), and beta-hemolytic streptococci ( n = 3), the MICs ranged from 0.03 to 0.25 μg/ml for tedizolid and from 0.12 to 1 μg/ml for linezolid. The microbiological eradication rates at the test-of-cure visit (7 to 14 days posttreatment) in the microbiologically evaluable population ( n = 133) were similar in all treatment groups, with overall eradication rates of 97.7% for all pathogens, 97.9% for MRSA, and 95.7% for MSSA. The clinical cure rates for MRSA and MSSA infections were 96.9% and 95.7%, respectively, across all dose groups. This study confirms the potent in vitro activity of tedizolid against pathogenic Gram-positive cocci, including MRSA, and its 4-fold-greater potency in comparison with linezolid. All dosages of tedizolid phosphate showed excellent microbiological and clinical efficacy against MRSA and MSSA.Keywords
This publication has 32 references indexed in Scilit:
- In Vivo Pharmacodynamics of Torezolid Phosphate (TR-701), a New Oxazolidinone Antibiotic, against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Strains in a Mouse Thigh Infection ModelAntimicrobial Agents and Chemotherapy, 2011
- Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2011
- Comparative Activities of TR-700 (Torezolid) against Staphylococcal Blood Isolates Collected in SpainAntimicrobial Agents and Chemotherapy, 2010
- Comparative In Vitro Antimicrobial Activities of Torezolid (TR-700), the Active Moiety of a New Oxazolidinone, Torezolid Phosphate (TR-701), Determination of Tentative Disk Diffusion Interpretive Criteria, and Quality Control RangesAntimicrobial Agents and Chemotherapy, 2010
- In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial AgentAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant StrainsAntimicrobial Agents and Chemotherapy, 2008
- First Report of cfr -Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United StatesAntimicrobial Agents and Chemotherapy, 2008
- Linezolid Resistance in Staphylococcus aureus : Gene Dosage Effect, Stability, Fitness Costs, and Cross-ResistancesAntimicrobial Agents and Chemotherapy, 2008
- High Frequencies of Clindamycin and Tetracycline Resistance in Methicillin-Resistant Staphylococcus aureus Pulsed-Field Type USA300 Isolates Collected at a Boston Ambulatory Health CenterJournal of Clinical Microbiology, 2007
- Prevalence of Inducible Clindamycin Resistance among Community- and Hospital-Associated Staphylococcus aureus IsolatesJournal of Clinical Microbiology, 2006